Gerber reboots whey protein formula petition
This article was originally published in The Tan Sheet
Executive Summary
Nestle Infant Nutrition asks FDA to allow a qualified health claim that 100-percent whey-protein partially hydrolyzed infant formula "may reduce the risk of developing the most common allergic disease of infancy -- atopic dermatitis" in infants not exclusively breastfed. The subsidiary of Florham Park, N.J.-based Gerber Products adds in a May 14 citizen 1petition that partially hydrolyzed formulas are not meant to treat existing food allergy symptoms. FDA posted the petition July 21. In 2005, FDA denied a request by Nestle Infant Nutrition, then a Nestle USA division, for a food allergy QHC for whey protein formula (2"The Tan Sheet" May 22, 2006). The firm says its resubmitted petition has a reworded claim and includes additional supporting science
You may also be interested in...
FDA Denies Claim Linking Hydrolyzed Infant Formula To Reduced Allergies
There is "no credible scientific evidence" to support a qualified health claim linking consumption of 100% partially hydrolyzed whey protein infant formula (PHF-W) to a reduced risk of the development of food allergies, FDA concludes in a May 11 letter to petitioner Nestlé USA
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.